Jinyan Liu Selected Research

Jinyan Liu Research Topics

Disease

16	Infections 01/2022 - 10/2010
15	Neoplasms (Cancer) 05/2022 - 11/2014
15	COVID-19 01/2022 - 01/2020
6	Esophageal Squamous Cell Carcinoma 01/2022 - 09/2015
4	Vaccinia 05/2022 - 04/2006
3	Wounds and Injuries (Trauma) 08/2022 - 03/2016
3	Melanoma (Melanoma, Malignant) 01/2021 - 03/2017
3	Inflammation (Inflammations) 11/2020 - 04/2014
3	Fibrosis (Cirrhosis) 01/2019 - 11/2014
2	Neoplasm Metastasis (Metastasis) 03/2022 - 08/2017
2	Viremia 01/2020 - 01/2017
1	Alzheimer Disease (Alzheimer's Disease) 05/2022
1	Osteosarcoma (Osteogenic Sarcoma) 03/2022
1	Carcinogenesis 03/2022
1	Breakthrough Infections 01/2022
1	Severe Acute Respiratory Syndrome 01/2022
1	Pain (Aches) 10/2021
1	Headache (Headaches) 10/2021
1	Non-alcoholic Fatty Liver Disease 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Fever (Fevers) 01/2021
1	Metabolic Diseases (Metabolic Disease) 01/2021
1	Obesity 01/2021
1	Disease Progression 01/2021
1	Circulating Neoplastic Cells 01/2020
1	Dengue (Dengue Fever) 01/2020
1	Colorectal Neoplasms (Colorectal Cancer) 01/2020
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2020
1	Lymphopenia (Lymphocytopenia) 01/2020
1	Diabetic Nephropathies (Diabetic Nephropathy) 01/2019
1	Body Weight (Weight, Body) 01/2019
1	Graves Ophthalmopathy 08/2018

Drug/Important Bio-Agent (IBA)

22	VaccinesIBA 05/2022 - 04/2004
7	Proteins (Proteins, Gene)FDA Link 05/2022 - 04/2006
7	Messenger RNA (mRNA)IBA 03/2022 - 11/2014
6	Ad26COVS1IBA 01/2022 - 01/2021
5	AntibodiesIBA 01/2021 - 10/2013
4	AntigensIBA 08/2017 - 10/2013
3	mRNA VaccinesIBA 01/2022 - 01/2021
3	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
3	CytokinesIBA 01/2020 - 04/2004
3	Antiviral Agents (Antivirals)IBA 01/2020 - 04/2016
3	Broadly Neutralizing AntibodiesIBA 01/2020 - 01/2017
3	DNA (Deoxyribonucleic Acid)IBA 01/2017 - 04/2007
2	vesatolimodIBA 05/2022 - 11/2018
2	Neutralizing AntibodiesIBA 01/2022 - 01/2021
2	Biological ProductsIBA 06/2021 - 01/2015
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 01/2021 - 01/2018
2	KynurenineIBA 12/2018 - 01/2018
2	Aryl Hydrocarbon Receptors (Aryl Hydrocarbon Receptor)IBA 12/2018 - 01/2018
2	Biomarkers (Surrogate Marker)IBA 08/2017 - 03/2017
2	Granzymes (Granzyme)IBA 09/2015 - 11/2014
1	Deferoxamine (Desferal)FDA LinkGeneric 08/2022
1	ferrostatin-1IBA 08/2022
1	Fluorescent Dyes (Fluorescent Probes)IBA 05/2022
1	Peroxynitrous Acid (Peroxynitrite)IBA 05/2022
1	2-oxindole (oxindole)IBA 05/2022
1	Amyloid (Amyloid Fibrils)IBA 05/2022
1	NaphthalimidesIBA 05/2022
1	aluminum sulfate (alum)IBA 05/2022
1	GP 140IBA 05/2022
1	Sincalide FDA Link 03/2022
1	InterferonsIBA 01/2022
1	Proteasome Endopeptidase Complex (Proteasome)IBA 01/2022
1	Indicators and Reagents (Reagents)IBA 01/2022
1	Monoclonal AntibodiesIBA 10/2021
1	COVID-19 VaccinesIBA 01/2021
1	BNT162 VaccineIBA 01/2021
1	2019-nCoV Vaccine mRNA-1273IBA 01/2021
1	Protein Subunit VaccinesIBA 01/2021
1	EpitopesIBA 01/2021
1	Viral AntigensIBA 01/2021
1	Cysteine (L-Cysteine)FDA Link 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2021
1	Triglycerides (Triacylglycerol)IBA 01/2021
1	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2021
1	epacadostatIBA 01/2021
1	tilianinIBA 11/2020
1	Chimeric Antigen ReceptorsIBA 10/2020
1	LipidsIBA 01/2020
1	RV 538 (PDMP)IBA 01/2020
1	CeramidesIBA 01/2020
1	Epithelial Cell Adhesion MoleculeIBA 01/2020
1	Immune Checkpoint ProteinsIBA 01/2020
1	Glucose (Dextrose)FDA LinkGeneric 01/2019
1	Silybin (Lagosa)IBA 01/2019
1	Immune Checkpoint InhibitorsIBA 12/2018
1	Polysaccharides (Glycans)IBA 11/2018
1	Toll-Like Receptors (Toll-Like Receptor)IBA 11/2018
1	Epoxide HydrolasesIBA 10/2018
1	Ethanol (Ethyl Alcohol)IBA 10/2018
1	Troleandomycin (TAO)FDA Link 08/2018

Therapy/Procedure

7	Therapeutics 05/2022 - 11/2014
2	Immunotherapy 08/2017 - 03/2017
1	Intravenous Injections 10/2021
1	Aftercare (After-Treatment) 01/2021
1	Cell- and Tissue-Based Therapy (Cell Therapy) 01/2021
1	Drug Therapy (Chemotherapy) 11/2020
1	Punctures 06/2019